Logo

NIVF

NewGenIvf Group Limited

NIVF

NewGenIvf Group Limited • NASDAQ
$0.35 ▲ 8.06% (+0.03)
Market Cap $646949
52w High $2735.00
52w Low $0.33
Dividend Yield 0%
P/E 0.01
Volume 2.42M
Outstanding Shares 1.83M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $1.274M ▼ $1.449M ▲ $-108K ▼ -8.477% ▼ $-4.75 ▼ $58.327K ▼
Q3-2024 $1.473M ▼ $429.898K ▼ $-19.857K ▲ -1.348% ▲ $-1.35 ▼ $226.87K ▼
Q4-2023 $1.519M ▲ $1.266M ▲ $-955K ▼ -62.851% ▼ $33.05 ▲ $451.847K ▲
Q3-2023 $0 $377.717K ▲ $127.021K ▲ 0% $23.45 ▲ $127.021K ▲
Q2-2023 $0 $367K $85.497K 0% $15.75 $85.496K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $457.74K ▲ $3.782M ▲ $5.06M ▼ $-844.614K ▲
Q3-2024 $169.661K ▲ $1.473M ▼ $8.548M ▲ $-6.585M ▼
Q4-2023 $54.104K ▼ $4.487M ▼ $1.241M ▼ $15.597M ▼
Q3-2023 $39.293M ▲ $39.342M ▲ $4.433M ▲ $34.908M ▲
Q2-2023 $77.294K $38.673M $3.892M $34.781M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-108.243K ▲ $-6.354M ▼ $13.588K ▼ $6.597M ▲ $288.079K ▲ $-6.357M ▼
Q4-2023 $-955.489K ▼ $-142.705K ▲ $18.373M ▲ $-18.227M ▼ $3.47K ▲ $-142.709K ▲
Q3-2023 $127.021K ▼ $-203.277K ▼ $-248.28K ▼ $368.736K ▲ $-82.815K ▼ $-203.277K ▼
Q4-2022 $474.362K ▲ $-34.671K ▼ $-241.792K ▼ $243.811K ▲ $-32.652K ▼ $-34.671K ▼
Q3-2022 $208.323K $-22.7K $-18.825K $18.982K $-22.543K $-22.7K

Five-Year Company Overview

Income Statement

Income Statement NewGenIvf’s reported income statement is extremely small in scale and not yet very informative. Revenue is tiny, with no clear sign of a mature, operating business behind the numbers. Profit measures and margins are essentially flat in the disclosures, while reported earnings per share swing sharply from positive to very negative, which likely reflects changes in capital structure or one‑off accounting items more than true business performance. Overall, the company looks to be in a very early or transition stage where the “story” and growth plans matter more than the historic income statement. Key implication: past results do not yet show a stable, proven earnings profile; future results could move around a lot as the business actually scales up or restructures.

Balance Sheet

Balance Sheet The balance sheet data shows very modest reported assets and equity, and essentially no recorded debt or cash. That combination suggests either very lean operations or incomplete reporting for the period. In any case, the numbers do not point to a company with a large financial cushion yet. The string of reverse stock splits in 2025 also hints that shares have been under pressure and that management has been adjusting the share structure, often a sign of a company still trying to find its footing in public markets. Key implication: the financial base appears thin, and the business likely relies on future funding or successful execution of its growth plans to strengthen the balance sheet over time.

Cash Flow

Cash Flow Cash flow information is limited but indicates slightly negative operating and free cash flow in the most recent year, with little visible activity before that. This is typical of an early‑stage or ramp‑up business: cash is going out to fund operations and expansion before meaningful cash comes in from customers. Key implication: the company appears to be in an investment and build‑out phase, dependent on external capital or future revenue growth rather than internally generated cash at this stage.

Competitive Edge

Competitive Edge NewGenIvf operates in a niche of the fertility market with a distinctive focus on advanced sperm sorting. Its NewGenSort technology, patents, and ownership of specialized equipment provide a technical barrier to entry that many standard IVF clinics do not have. The company already runs a network of fertility services in select Asian markets and aims to bring this specialized capability into the U.S., where demand for assisted reproduction is large and growing. On the other hand, the broader fertility industry is crowded, regulated, and sensitive to ethical debates, especially around sex selection and genetic issues. NewGenIvf must establish trusted partnerships with clinics, gain regulatory comfort, and build brand recognition in markets where it is not yet well known. Key implication: the company has a clear technical angle and niche, but its real competitive strength will depend on how well it converts that technology into trusted, widely adopted clinical services in major markets.

Innovation and R&D

Innovation and R&D Innovation is the centerpiece of NewGenIvf’s story. The NewGenSort platform, derived from MicroSort technology, is a sophisticated application of cell sorting and fluorescent staining, with patents and specialized hardware backing it. The company has acquired multiple sorting systems and related intellectual property, giving it capacity and a degree of exclusivity. This creates a foundation for ongoing experimentation, potential accuracy improvements, and new medical applications (for example, reducing certain genetic risks). At the same time, the company has signaled interest in ventures outside pure fertility, such as digital asset management and art tokenization. Those areas are far from its core medical focus and introduce strategic complexity and execution risk if they draw resources or attention away from its main technological edge. Key implication: the core fertility technology and related patents are a genuine strength, but the value will depend on disciplined R&D and staying focused on medical applications rather than drifting too far into unrelated experiments.

Summary

NewGenIvf is best viewed as an early‑stage, technology‑driven fertility platform rather than a mature, cash‑generating healthcare business. The historical financials are tiny and inconsistent, with thin assets, minimal cash visibility, and negative cash flow that reflect a build‑out phase rather than an established operation. Multiple reverse stock splits underline that the public‑market journey has been bumpy. On the opportunity side, the company has a distinctive, patented sperm‑sorting technology, a presence in fast‑growing Asian fertility markets, and a clear ambition to expand into the U.S. If it can secure regulatory acceptance, clinic partnerships, and strong clinical outcomes, that combination could carve out a recognizable niche in assisted reproduction. On the risk side, execution demands are high: scaling operations, managing ethical and regulatory scrutiny, maintaining scientific leadership, and avoiding distraction from non‑core ventures. Overall, this is a story where the future depends far more on successful commercialization and expansion than on what the recent financial statements currently show.

NEWS

November 10, 2025 · 8:30 AM UTC

NewGen Announces Up to US$2 Million Share Repurchase Program

Read more

November 5, 2025 · 9:00 AM UTC

NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

Read more

November 3, 2025 · 9:00 AM UTC

NewGen Announces Proposed Reverse Merger with SAXA, Inc. in a $5 Billion Mining Asset Acquisition Deal, Involving Gold, Silver, and Rare Earth

Read more

October 31, 2025 · 8:30 AM UTC

NewGen Enters Into an Innovative Digital Assets Purchase Agreement with White Lion to Acquire up to 600,000 Solana Tokens Valued at Over $110 Million

Read more

October 20, 2025 · 8:30 AM UTC

NewGen Announces Strategic Entry into Art Tokenization Market with $2 Million Private Collection Deal, Expandable to $200 Million

Read more